In testimony before the Food and Drug Administration’s (FDA’s) Peripheral and Central Nervous System Drugs Advisory Committee, which was convened to reconsider whether the combination drug AMX0035 (sodium phenylbutyrate and taurursodiol) should be approved for treating amyotrophic lateral sclerosis, Public Citizen argued against approval because additional analyses of data from a clinical trial of the drug again failed to provide substantial evidence of effectiveness. Testimony Before the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee Regarding the Drug AMX0035 for Treatment of Amyotrophic Lateral Sclerosis (HRG Publication #2637) Sidney Wolfe explains why Congress needs to enact further legislation to curb the perverse systemic financial incentives that contribute to the high prices of prescription drugs in the U.S.

In an invited commentary published in JAMA Internal Medicine, Public Citizen’s Dr.

Invited Commentary Published in JAMA Internal Medicine: Curbing the Financial Incentives That Contribute to the High Prices of Prescription Drugs in the US (HRG Publication #2638)

Ivanti error code 1618